generation run 2026-05-13
56 min completedmodel pipeline-v5plan not recordedrun/73845b2f…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- sparse_evidence
- taper_not_applicable
Reproduce
- inputs
- 38 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
20 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | cocoa theobromine pharmacology mechanism receptor | 6 | 4 | Core mechanistic pharmacology papers for theobromine and caffeine in cocoa |
| 2 | PubMed | Theobroma cacao alkaloids theobromine caffeine phytochemistry | 1 | 1 | Key review on caffeine/theobromine biosynthesis in Theobroma and related plants |
| 3 | PubMed | cocoa flavanols polyphenols health effects cardiovascular | 10 | 3 | High-quality RCTs and systematic reviews on cocoa health effects |
| 4 | PubChem | theobromine, caffeine, phenethylamine, anandamide | 4 | 4 | Core active constituents of cocoa confirmed |
| 5 | OpenAlex | Theobroma cacao cocoa phytochemistry constituents methylxanthines flavonoids | 10 | 4 | High-citation papers covering cocoa phytochemistry and health effects |
| 6 | WebSearch | Theobroma cacao POWO accepted taxonomy family Malvaceae native range synonyms | 10 | 2 | Confirms botanical taxonomy |
| 7 | PubMed | cocoa chocolate heavy metal cadmium lead contamination safety | 8 | 4 | Safety-critical contaminant data: cadmium in cocoa major documented concern |
| 8 | POWO (Plants of the World Online) | Theobroma cacao taxonomy | 1 | 1 | Authoritative taxonomy source |
| 9 | PubMed | chocolate phenylethylamine tyramine biogenic amine content analysis | 1 | 1 | Confirms phenylethylamine/tyramine presence in chocolate via fermentation |
| 10 | PubMed | Theobroma cacao genetics cultivar criollo forastero trinitario genotype | 1 | 1 | Key paper on cultivar genetics and domestication history |
| 11 | PubMed | cocoa cacao Maya evidence residue history | 1 | 1 | Foundational archaeological evidence of earliest Maya cacao use, Nature publication |
| 12 | ClinicalTrials.gov | cocoa flavanols cognitive function randomized | 6 | 4 | Active clinical research base on cocoa cognitive/neurological effects |
| 13 | OpenAlex | Theobroma cacao history ethnobotany Maya Aztec Mesoamerica chocolate | 10 | 3 | Key ethnobotanical and archaeological literature on cacao origin and indigenous use |
| 14 | WebSearch | Theobroma cacao Linnaeus 1753 history European introduction colonial Mexico | 10 | 2 | Historical context for ethnobotany section |
| 15 | PubMed | theobromine cough antitussive effect clinical trial | 1 | 1 | Pharmacological effect of theobromine beyond CNS/cardiovascular — antitussive clinical RCT |
| 16 | Multiple PubMed + OpenAlex sources | Theobromine/caffeine quantitative data in cocoa | 5 | 3 | Quantitative alkaloid data for alkaloid profile section |
| 17 | PubMed | di Tomaso Beltramo Piomelli chocolate brain cannabinoid | 1 | 3 | Key papers on endocannabinoid-mimic hypothesis for chocolate — relevant to psychoactive effects discussion |
| 18 | OpenAlex | cocoa blood pressure meta-analysis systematic review | 8 | 1 | Highest quality evidence on cocoa cardiovascular effects — Cochrane review |
| 19 | PubMed | caffeine pregnancy birth outcomes systematic review | 4 | 1 | Safety: pregnancy contraindication data for caffeine in cocoa |
| 20 | OpenAlex | theobromine pharmacology cardiovascular respiratory stimulant mechanism | 10 | 2 | Foundational pharmacology reviews on theobromine mechanism |
143 claims by section — every cited sentence, checked against its source
safety50 · 2 ok
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
At 125-200 mg/kg/day, fetal weight decreases and skeletal malformations were observed, while dietary exposure at 63 mg/kg/day or less showed no fetotoxicity or teratogenicity.supported
Developmental variations at 125-200 mg/kg. No teratogenicity at dietary levels. Highest test doses 38x human maximum consumption. pmid:3744189
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
A meta-analysis of 60 studies found that each 100 mg increment in daily caffeine intake was associated with a 14% increase in spontaneous abortion risk, a 19% increase in stillbirth risk, and a 10% increase in small-for-gestational-age birth risksupported
Meta-analysis of 60 publications: per 100mg caffeine increment associated with 14% increased spontaneous abortion risk, 19% stillbirth, 7% low birth weight, 10% SGA. s10654-014-9944-x
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
alkaloid-profile26 · 0 ok
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
Claim in alkaloid-profile — inconclusiveinconclusiveworking →
neuroscience20 · 3 ok
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
At physiologically relevant concentrations (30 uM), theobromine facilitates synaptic transmission via A1R blockade and impairs long-term potentiation via A2AR blockade in hippocampal neuronssupported
Theobromine (30 uM) facilitated synaptic transmission while decreasing LTP magnitude. A1R antagonist eliminated theobromine-dependent facilitation; A2AR antagonist abrogated LTP impairment. ijms231810510
This dual action also confers neuroprotection against amyloid-beta1-42-induced neuronal loss in vitro. Caffeine shares these receptor targets but is present in cocoa at approximately one-tenth the concentration of theobrominepartially supported
Theobromine prevented LTP deficits and neuronal loss in Abeta1-42 exposed hippocampal preparations. ijms231810510
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
The proposed mechanism is peripheral inhibition of capsaicin-induced sensory nerve depolarization of the vagus nerve, a pathway distinct from adenosine receptor antagonism.supported
Theobromine directly inhibits capsaicin-induced sensory nerve depolarization of guinea-pig and human vagus nerve suggestive of an inhibitory effect on afferent nerve activation. Actions of theobromine appear to be peripherally mediated. pmid:15548587
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
preparations20 · 0 ok
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
Claim in preparations — inconclusiveinconclusiveworking →
summary13 · 1 ok
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Theobromine exerts its primary central and peripheral effects through antagonism of adenosine A1 and A2A receptors and inhibition of phosphodiesterases, increasing intracellular cAMPpartially supported
A1R antagonist eliminated theobromine-dependent facilitation; A2AR antagonist abrogated LTP impairment. ijms231810510
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
history12 · 0 ok
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →